Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Jul 2021
Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage
21 July 2021 - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a ...
Posted by Michael Wonder on 21 Jul 2021
Pfizer provides update on U.S. FDA review of abrocitinib and Xeljanz filings
21 July 2021 - Pfizer announced today that the U.S. FDA has notified the company that it will not meet the ...
Posted by Michael Wonder on 21 Jul 2021
Americans’ medical debts are bigger than was known, totalling $140 billion
20 July 2021 - A new study finds that health care has become the country’s largest source of debt in collections. ...
Posted by Michael Wonder on 21 Jul 2021
How an unproven Alzheimer’s drug got approved
19 July 2021 - Though some of its own senior officials said there was little evidence of benefit for patients, the ...
Posted by Michael Wonder on 21 Jul 2021
Myovant Sciences announces European Commission approval for Ryeqo for the treatment of women with uterine fibroids
20 July 2021 - Ryeqo is the first and only once-daily long-term treatment for uterine fibroids in Europe. ...
Posted by Michael Wonder on 21 Jul 2021
Sorrento announces its partner Mabpharm has received marketing approval in China for infliximab biobetter
20 July 2021 - Sorrento to exclusively market the product outside of China including US, Japan and Europe. ...
Posted by Michael Wonder on 21 Jul 2021
EMA publishes agenda for 19-22 July CHMP meeting
19 July 2021 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 21 Jul 2021
Venetoclax (Venclexta) granted US FDA breakthrough therapy designation in higher risk myelodysplastic syndrome
21 July 2021 - This is the sixth breakthrough therapy designation granted for venetoclax as AbbVie continues to show ongoing commitment ...
Posted by Michael Wonder on 21 Jul 2021
U.S. FDA expands indication for Prograf for prevention of organ rejection in adult and paediatric lung transplant recipients
21 July 2021 - Prograf becomes first immunosuppressive drug approved in the U.S. for people receiving a lung transplant. ...
Posted by Michael Wonder on 21 Jul 2021
New treatment authorised and available for Canadians with HER2 positive breast cancer
20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...
Posted by Michael Wonder on 20 Jul 2021
Biden administration seeks higher penalties for hospitals that don't publish prices
19 July 2021 - The Biden administration is proposing to increase the penalty for hospitals that don't comply with a ...
Posted by Michael Wonder on 20 Jul 2021
Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
20 July 2021 - The very next day after Republican Scott Peters attempted to torpedo House Speaker Nancy Pelosi’s signature drug ...
Posted by Michael Wonder on 20 Jul 2021
Albireo announces FDA approval of Bylvay (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis
20 July 2021 - Commercial launch of Bylvay immediate; available for prescription in the coming days. ...
Posted by Michael Wonder on 20 Jul 2021
NeuroMetrix receives FDA breakthrough device designation for treatment of fibromyalgia with its wearable neurostimulation technology
20 July 2021 - NeuroMetrix today announced that its Quell device has received breakthrough designation from the U.S. FDA for treating ...
Posted by Michael Wonder on 20 Jul 2021
FDA approves Octapharma’s Octagam 10% for adult dermatomyositis
20 July 2021 - FDA approval based on positive results of international, multi-center ProDERM study. ...